An Empirical Study of Performance Evaluation Method EVA-based for Telecom Operators

Combining with EVA-based operation value chain of telecom operators, this paper researches the EVA evaluation scheme introduced by SASAC for central enterprises. In this paper, we design the model of EVA and OPE, ROI, ROE by using the regression analysis method firstly, then find out the relationship between EVA and traditional performance evaluation indexes by combining with the annual report three of telecom operators published in recent years. From the empirical study of Performance Evaluation Method EVA-based, we can find that EVA evaluation scheme is propitious to enhance the management and incentive effect of telecom operators, and promote the development of telecom industry healthily and stably. Key words: EVA; Operation value chain; Performance evaluation; Regression analysi

TransY-Net:Learning Fully Transformer Networks for Change Detection of Remote Sensing Images

In the remote sensing field, Change Detection (CD) aims to identify and localize the changed regions from dual-phase images over the same places. Recently, it has achieved great progress with the advances of deep learning. However, current methods generally deliver incomplete CD regions and irregular CD boundaries due to the limited representation ability of the extracted visual features. To relieve these issues, in this work we propose a novel Transformer-based learning framework named TransY-Net for remote sensing image CD, which improves the feature extraction from a global view and combines multi-level visual features in a pyramid manner. More specifically, the proposed framework first utilizes the advantages of Transformers in long-range dependency modeling. It can help to learn more discriminative global-level features and obtain complete CD regions. Then, we introduce a novel pyramid structure to aggregate multi-level visual features from Transformers for feature enhancement. The pyramid structure grafted with a Progressive Attention Module (PAM) can improve the feature representation ability with additional inter-dependencies through spatial and channel attentions. Finally, to better train the whole framework, we utilize the deeply-supervised learning with multiple boundary-aware loss functions. Extensive experiments demonstrate that our proposed method achieves a new state-of-the-art performance on four optical and two SAR image CD benchmarks. The source code is released at https://github.com/Drchip61/TransYNet.Comment: This work is accepted by TGRS2023. It is an extension of our ACCV2022 paper and arXiv:2210.0075

2023 Low-Power Computer Vision Challenge (LPCVC) Summary

This article describes the 2023 IEEE Low-Power Computer Vision Challenge (LPCVC). Since 2015, LPCVC has been an international competition devoted to tackling the challenge of computer vision (CV) on edge devices. Most CV researchers focus on improving accuracy, at the expense of ever-growing sizes of machine models. LPCVC balances accuracy with resource requirements. Winners must achieve high accuracy with short execution time when their CV solutions run on an embedded device, such as Raspberry PI or Nvidia Jetson Nano. The vision problem for 2023 LPCVC is segmentation of images acquired by Unmanned Aerial Vehicles (UAVs, also called drones) after disasters. The 2023 LPCVC attracted 60 international teams that submitted 676 solutions during the submission window of one month. This article explains the setup of the competition and highlights the winners' methods that improve accuracy and shorten execution time.Comment: LPCVC 2023, website: https://lpcv.ai

Secure Energy-Efficient Resource Allocation Algorithm of Massive MIMO System with SWIPT

In this paper, we consider the resource allocation problem to maximize the minimum (max–min) user’s secure energy efficiency (SEE) in downlink massive multiple-input multiple-output (MIMO) systems with simultaneous wireless information and power transfer (SWIPT). First, transmission power and power splitting ratio are designed to achieve the max–min user’s SEE subject to harvested energy threshold, the constraints of transmission power, and power splitting ratio. Secondly, the optimization problem is non-convex and very difficult to tackle. In order to solve the optimization problem, we converted to a series of parameter optimization subproblems by fractional programming. Then, we employ the first-order Taylor expansion and successive convex approximation (SCA) method to solve parameter optimization problems. Next, a secure energy-efficient resource allocation (SERA) algorithm with the bisection method is proposed to find the max–min SEE of the system. Finally, simulation results show the effectiveness and superiority of the SERA algorithm

Unimolecular Self-Assembled Hemicyanine–Oleic Acid Conjugate Acts as a Novel Succinate Dehydrogenase Inhibitor to Amplify Photodynamic Therapy and Eliminate Cancer Stem Cells

Photodynamic therapy with reactive oxygen species production is a prospective treatment to combat cancer stem cells (CSCs). However, the innate drawbacks, including short lifetime and diffusion distance of reactive oxygen species and hypoxia within solid tumors, have become bottlenecks for clinical applications of photodynamic therapy. Here, we develop a mitochondria-targeting hemicyanine–oleic acid conjugate (CyOA), which can self-assemble into supramolecular nanoparticles (NPs) without any exogenous excipients. CyOA is also shown for targeting the mitochondrial complex II protein succinate dehydrogenase to inhibit oxidative phosphorylation and reverse tumor hypoxia, resulting in 50.4-fold higher phototoxicity against breast cancer stem cells (BCSCs) compared to SO3-CyOA NPs that cannot target to mitochondria. In 4T1 and BCSC tumor models, CyOA NPs achieve higher tumor inhibition and less lung metastasis nodules compared to the clinically used photosensitizer Hiporfin. This study develops a self-assembled small molecule that can serve as both oxidative phosphorylation inhibitor and photosensitizer for eradication of CSCs and treatment of solid tumors

α‑Amylase- and Redox-Responsive Nanoparticles for Tumor-Targeted Drug Delivery

Paclitaxel (PTX) is an effective antineoplastic agent and shows potent antitumor activity against a wide spectrum of cancers. Yet, the wide clinical use of PTX is limited by its poor aqueous solubility and the side effects associated with its current therapeutic formulation. To tackle these obstacles, we report, for the first time, α-amylase- and redox-responsive nanoparticles based on hydroxyethyl starch (HES) for the tumor-targeted delivery of PTX. PTX is conjugated onto HES by a redox-sensitive disulfide bond to form HES–SS-PTX, which was confirmed by results from NMR, high-performance liquid chromatography-mass spectrometry, and Fourier transform infrared spectrometry. The HES–SS-PTX conjugates assemble into stable and monodispersed nanoparticles (NPs), as characterized with Dynamic light scattering, transmission electron microscopy, and atomic force microscopy. In blood, α-amylase will degrade the HES shell and thus decrease the size of the HES–SS-PTX NPs, facilitating NP extravasation and penetration into the tumor. A pharmacokinetic study demonstrated that the HES–SS-PTX NPs have a longer half-life than that of the commercial PTX formulation (Taxol). As a consequence, HES–SS-PTX NPs accumulate more in the tumor compared with the extent of Taxol, as shown in an in vivo imaging study. Under reductive conditions, the HES–SS-PTX NPs could disassemble quickly as evidenced by their triggered collapse, burst drug release, and enhanced cytotoxicity against 4T1 tumor cells in the presence of a reducing agent. Collectively, the HES–SS-PTX NPs show improved in vivo antitumor efficacy (63.6 vs 52.4%) and reduced toxicity in 4T1 tumor-bearing mice compared with those of Taxol. These results highlight the advantages of HES-based α-amylase- and redox-responsive NPs, showing their great clinical translation potential for cancer chemotherapy

Enhancing Doxorubicin Delivery toward Tumor by Hydroxyethyl Starch‑<i>g</i>‑Polylactide Partner Nanocarriers

Doxorubicin (DOX), a kind of wide-spectrum chemotherapeutic drug, can cause severe side effects in clinical use. To enhance its antitumor efficacy while reducing the side effects, two kinds of nanoparticles with desirable compositions and properties were assembled using optimally synthesized hydroxyethyl starch-grafted-polylactide (HES-<i>g</i>-PLA) copolymers and utilized as partner nanocarriers. The large empty HES-<i>g</i>-PLA nanoparticles (mean size, <i>ca.</i> 700 nm), at an optimized dose of 400 mg/kg, were used to block up the reticuloendothelial system in tumor-bearing mice 1.5 h in advance, and the small DOX-loaded HES-<i>g</i>-PLA nanoparticles (mean size, <i>ca.</i> 130 nm) were subsequently applied to the mice. When these partner nanocarriers were administered in this sequential mode, the released DOX had a significantly prolonged plasma half-life time and much slower clearance rate as well as a largely enhanced intratumoral accumulation as compared to free DOX. <i>In vivo</i> antitumor studies demonstrated that the DOX-loaded HES-<i>g</i>-PLA nanoparticles working together with their partner exhibited remarkably enhanced antitumor efficacy in comparison to free DOX. In addition, these HES-<i>g</i>-PLA partner nanocarriers showed negligible damage to the normal organs of the treated mice. Considering safe and efficient antitumor performance of DOX-loaded HES-<i>g</i>-PLA nanoparticles, the newly developed partner nanocarriers in combination with their administration mode have promising potential in clinical cancer chemotherapy

A novel lonidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism

Cancer stem cells (CSCs) have been blamed as the main culprit of tumor initiation, progression, metastasis, chemoresistance, and recurrence. However, few anti-CSCs agents have achieved clinical success so far. Here we report a novel derivative of lonidamine (LND), namely HYL001, which selectively and potently inhibits CSCs by targeting mitochondria, with 380-fold and 340-fold lower IC50 values against breast cancer stem cells (BCSCs) and hepatocellular carcinoma stem cells (HCSCs), respectively, compared to LND. Mechanistically, we reveal that HYL001 downregulates glutaminase (GLS) expression to block glutamine metabolism, blunt tricarboxylic acid cycle, and amplify mitochondrial oxidative stress, leading to apoptotic cell death. Therefore, HYL001 displays significant antitumor activity in vivo, both as a single agent and combined with paclitaxel. Furthermore, HYL001 represses CSCs of fresh tumor tissues derived from liver cancer patients. This study provides critical implications for CSCs biology and development of potent anti-CSCs drugs

Transgenic Quail Production by Microinjection of Lentiviral Vector into the Early Embryo Blood Vessels

<div><p>Several strategies have been used to generate transgenic birds. The most successful method so far has been the injection of lentiviral vectors into the subgerminal cavity of a newly laid egg. We report here a new, easy and effective way to produce transgenic quails through direct injection of a lentiviral vector, containing an enhanced-green fluorescent protein (eGFP) transgene, into the blood vessels of quail embryos at Hamburger-Hamilton stage 13–15 (HH13–15). A total of 80 embryos were injected and 48 G0 chimeras (60%) were hatched. Most injected embryo organs and tissues of hatched quails were positive for eGFP. In five out of 21 mature G0 male quails, the semen was eGFP-positive, as detected by polymerase chain reaction (PCR), indicating transgenic germ line chimeras. Testcross and genetic analyses revealed that the G0 quail produced transgenic G1 offspring; of 46 G1 hatchlings, 6 were transgenic (6/46, 13.0%). We also compared this new method with the conventional transgenesis using stage X subgerminal cavity injection. Total 240 quail embryos were injected by subgerminal cavity injection, of which 34 (14.1%) were hatched, significantly lower than the new method. From these hatched quails semen samples were collected from 19 sexually matured males and tested for the transgene by PCR. The transgene was present in three G0 male quails and only 4/236 G1 offspring (1.7%) were transgenic. In conclusion, we developed a novel bird transgenic method by injection of lentiviral vector into embryonic blood vessel at HH 13–15 stage, which result in significant higher transgenic efficiency than the conventional subgerminal cavity injection.</p> </div